Cynthia Nijenhuis
Overview
Explore the profile of Cynthia Nijenhuis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lievense J, Nijenhuis C, Jedema I, Jonker-Hoogerkamp A, Moyers J, Hamid O, et al.
Transplant Cell Ther
. 2025 Mar;
31(3S):S610-S625.
PMID: 40089330
Tumor-infiltrating lymphocyte (TIL) medicinal products (MPs) show promise for treating solid tumors, especially metastatic melanoma, in the clinical trial setting. Through these studies, TIL developers have gained an immunological perspective...
2.
Ten Ham R, Rohaan M, Jedema I, Kessels R, Stegeman W, Scheepmaker W, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38531663
Introduction: In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared with ipilimumab...
3.
Rohaan M, Borch T, van den Berg J, Met O, Kessels R, Geukes Foppen M, et al.
N Engl J Med
. 2022 Dec;
387(23):2113-2125.
PMID: 36477031
Background: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials...
4.
Dubbelman A, Rosing H, Nijenhuis C, Huitema A, Mergui-Roelvink M, Gupta A, et al.
Invest New Drugs
. 2014 Nov;
33(1):233-40.
PMID: 25377392
Lenvatinib is an orally available multi-targeted tyrosine kinase inhibitor with anti-angiogenic and antitumor activity. To get more insight into the disposition of lenvatinib, a mass balance study was performed in...